Valuation: Haleon plc

Market Cap 31.85B 42.39B 37.28B 34.63B 59.74B 4,105B 60.81B 414B 162B 2,002B 159B 156B 6,946B P/E 2026 *
18.7x
P/E 2027 * 16.9x
Enterprise Value 38.77B 51.59B 45.37B 42.15B 72.7B 4,996B 74B 504B 197B 2,437B 194B 189B 8,454B EV / Sales 2026 *
3.4x
EV / Sales 2027 * 3.22x
Free-Float
99.42%
Yield 2026 *
2.21%
Yield 2027 * 2.46%
1 day+0.91%
1 week-2.41%
Current month+4.77%
1 month+4.68%
3 months+2.56%
6 months-3.42%
Current year-2.80%
1 week 358.4
Extreme 358.4
373.1
1 month 344.2
Extreme 344.2
377.5
Current year 317.8
Extreme 317.8
416.1
1 year 274.4
Extreme 274.4
416.1
3 years 274.4
Extreme 274.4
419.5
5 years 241.17
Extreme 241.1735
419.5
10 years 241.17
Extreme 241.1735
419.5
Manager TitleAgeSince
Chief Executive Officer 59 2021-07-21
Director of Finance/CFO 57 2024-10-31
Chief Tech/Sci/R&D Officer 63 2025-07-31
Director TitleAgeSince
Director/Board Member 59 2022-05-22
Chairman 71 2025-12-31
Director/Board Member 59 2022-07-17
Date Insider Type Main position Quantity % Market Cap.
6/30/26 Free

Chief Financial Officer

283,193 0.0032%
6/30/26 Tax

Chief Financial Officer

-133,301 0.0015%
5/19/26 Buy 24,891 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
+0.75%-2.41%-0.19%+8.33% 42.39B
+1.40%+1.60%+48.74%+160.82% 1,057B
+1.54%+3.89%+55.04%+53.66% 624B
+1.08%+1.85%+35.83%+81.03% 454B
+1.60%+6.25%+33.95%+29.84% 341B
-0.60%+1.52%+35.68%+39.76% 297B
+0.57%+1.32%+17.00%+18.37% 262B
+0.09%-2.82%-28.29%-41.71% 215B
+1.45%+2.62%+21.83%+59.67% 201B
-0.31%-3.08%+14.97%+67.58% 162B
Average +0.79%+0.47%+23.46%+47.73% 365.63B
Weighted average by Cap. +1.05%+1.52%+35.42%+76.97%

Financials

2026 *2027 *
Net sales 11.4B 15.17B 13.34B 12.39B 21.38B 1,469B 21.76B 148B 57.81B 717B 56.95B 55.72B 2,486B 11.89B 15.82B 13.92B 12.93B 22.3B 1,532B 22.7B 155B 60.3B 747B 59.4B 58.12B 2,593B
Net income 1.74B 2.32B 2.04B 1.9B 3.27B 225B 3.33B 22.66B 8.84B 110B 8.71B 8.52B 380B 1.9B 2.53B 2.22B 2.07B 3.56B 245B 3.63B 24.72B 9.64B 119B 9.5B 9.29B 415B
Net Debt 6.91B 9.2B 8.09B 7.52B 12.97B 891B 13.2B 89.89B 35.06B 435B 34.54B 33.79B 1,508B 6.4B 8.52B 7.5B 6.96B 12.01B 825B 12.23B 83.27B 32.48B 403B 31.99B 31.3B 1,397B
Logo Haleon plc
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (29.5%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - Pain relief medicines (22.8%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - medicines for digestive health (17.7%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - vitamins, minerals and food supplements (15.1%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc. - respiratory medicines (14.9%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (41.2%), North America (36%), and Asia/Pacific (22.8%).
Employees
24,535
Date Price Change Volume
26-07-24 GBX 364.30 +0.75% 6,251,341
26-07-23 GBX 361.60 -1.18% 15,272,042
26-07-22 GBX 365.90 -0.73% 20,492,365
26-07-21 GBX 368.60 -0.65% 23,392,432
26-07-20 GBX 371.00 -0.62% 18,087,141
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
3.616GBP
Average target price
4.142GBP
Spread / Average Target
+14.56%

Quarterly revenue - Rate of surprise